3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Gemcitabine
169
130-nm albumin-bound paclitaxel
54
Albumin-Bound Paclitaxel
42
Oxaliplatin
32
Fluorouracil
31
pembrolizumab
30
Capecitabine
30
Leucovorin
27
Irinotecan
27
Radiotherapy
25
Nivolumab
22
Erlotinib Hydrochloride
21
Taxes
19
Cisplatin
18
Bevacizumab
15
Specimen Handling
12
Magnetic Resonance Spectroscopy
12
Radiosurgery
11
Ipilimumab
11
Cyclophosphamide
11
Drug Therapy
10
Carboplatin
10
Paclitaxel
9
Docetaxel
9
Cetuximab
9
Biopsy
9
trametinib
8
olaparib
8
Sorafenib
8
poly ICLC
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Pancreatic Neoplasms
×
AM0010
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled